Analysts See $-0.26 EPS for MEI Pharma, Inc. (MEIP); Princeton Portfolio Strategies Group Has Cut By $389,435 Its Stericycle (SRCL) Holding

January 14, 2018 - By Marie Mckinney

Analysts expect MEI Pharma, Inc. (NASDAQ:MEIP) to report $-0.26 EPS on February, 14.They anticipate $0.58 EPS change or 181.25% from last quarter’s $0.32 EPS. After having $-0.24 EPS previously, MEI Pharma, Inc.’s analysts see 8.33% EPS growth. The stock decreased 1.05% or $0.03 during the last trading session, reaching $2.36. About 146,737 shares traded. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 20.90% since January 14, 2017 and is uptrending. It has outperformed by 4.20% the S&P500.

Princeton Portfolio Strategies Group Llc decreased Stericycle Inc (SRCL) stake by 30.76% reported in 2017Q3 SEC filing. Princeton Portfolio Strategies Group Llc sold 5,485 shares as Stericycle Inc (SRCL)’s stock declined 1.87%. The Princeton Portfolio Strategies Group Llc holds 12,345 shares with $884,000 value, down from 17,830 last quarter. Stericycle Inc now has $6.11 billion valuation. The stock increased 0.03% or $0.02 during the last trading session, reaching $71.6. About 857,516 shares traded or 3.13% up from the average. Stericycle, Inc. (NASDAQ:SRCL) has declined 14.12% since January 14, 2017 and is downtrending. It has underperformed by 30.82% the S&P500.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company has market cap of $87.20 million. The companyÂ’s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. It currently has negative earnings. The Company’s clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer.

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. Oppenheimer maintained it with “Buy” rating and $6.5000 target in Wednesday, August 2 report. The firm earned “Hold” rating on Wednesday, September 6 by Stifel Nicolaus. Oppenheimer maintained MEI Pharma, Inc. (NASDAQ:MEIP) on Wednesday, June 14 with “Buy” rating. The firm has “Buy” rating by Oppenheimer given on Monday, June 26. Wedbush maintained the shares of MEIP in report on Friday, September 4 with “Hold” rating. Oppenheimer maintained it with “Buy” rating and $6.5000 target in Wednesday, May 31 report.

Among 15 analysts covering Stericycle (NASDAQ:SRCL), 5 have Buy rating, 3 Sell and 7 Hold. Therefore 33% are positive. Stericycle had 51 analyst reports since August 14, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $10800 target in Friday, July 7 report. Imperial Capital maintained the stock with “In-Line” rating in Monday, February 8 report. On Friday, August 26 the stock rating was initiated by Macquarie Research with “Neutral”. The company was maintained on Tuesday, October 10 by Robert W. Baird. The stock of Stericycle, Inc. (NASDAQ:SRCL) earned “Buy” rating by Jefferies on Friday, November 10. The company was initiated on Thursday, November 9 by Oppenheimer. The stock has “Perform” rating by Oppenheimer on Friday, October 23. The company was maintained on Friday, August 11 by Jefferies. The company was maintained on Wednesday, October 5 by Barrington Research. The stock of Stericycle, Inc. (NASDAQ:SRCL) has “Hold” rating given on Friday, April 29 by Stifel Nicolaus.

Since October 30, 2017, it had 0 insider purchases, and 1 sale for $1.39 million activity. Shares for $1.39 million were sold by MILLER MARK C.

Analysts await Stericycle, Inc. (NASDAQ:SRCL) to report earnings on February, 21. They expect $1.14 EPS, up 14.00% or $0.14 from last year’s $1 per share. SRCL’s profit will be $97.33 million for 15.70 P/E if the $1.14 EPS becomes a reality. After $1.10 actual EPS reported by Stericycle, Inc. for the previous quarter, Wall Street now forecasts 3.64% EPS growth.

Investors sentiment decreased to 0.89 in Q3 2017. Its down 0.05, from 0.94 in 2017Q2. It dived, as 42 investors sold SRCL shares while 185 reduced holdings. 54 funds opened positions while 148 raised stakes. 78.02 million shares or 2.16% more from 76.38 million shares in 2017Q2 were reported. Chesley Taft Associate Ltd Liability accumulated 0.03% or 5,045 shares. Ontario Teachers Pension Plan Board reported 0.22% stake. Morgan Stanley stated it has 0.01% of its portfolio in Stericycle, Inc. (NASDAQ:SRCL). Thompson Davis owns 93 shares. Mai Mngmt invested in 0.01% or 3,073 shares. Cibc Asset Mgmt invested in 9,384 shares. Eagleclaw Managment Limited Company reported 23,830 shares stake. Aviva Pcl stated it has 133,815 shares or 0.05% of all its holdings. Gam Ag holds 0.05% or 15,310 shares. De Burlo Gru Inc holds 0.09% of its portfolio in Stericycle, Inc. (NASDAQ:SRCL) for 5,400 shares. First Advsrs Limited Partnership owns 18,020 shares. Hsbc Plc owns 0.01% invested in Stericycle, Inc. (NASDAQ:SRCL) for 45,604 shares. Bernzott Advisors accumulated 0.03% or 3,308 shares. Kj Harrison Ptnrs invested in 11,600 shares or 0.29% of the stock. Caisse De Depot Et Placement Du Quebec reported 0% stake.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>